MMJ International Holdings Following FDA and DEA Federal Guidelines for Marijuana Drug Development

MMJ International Holdings Following FDA and DEA Federal Guidelines for Marijuana Drug Development

Publication date: Oct 05, 2019

MMJ International Holdings is developing an oral drug product from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

Most recently the FDA awarded MMJ International Holdings ″Orphan Drug Designation″ for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease.

“We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases,” said Duane Boise, CEO of MMJ International Holdings.

Tim Moynahan the company chairman stated that “Patients in the MMJ International holdings clinical trials will receive gelatin capsules containing THC and CBD daily.

Concepts Keywords
API Articles
Bear Health
Boise MS
Canada Treatment diseases
Cannabis Disease
Capsules Product seizures
CBD Cannabis pharmaceutical
CEO Manufacturing
CGMP Oral drug product
Chronic Diseases Liquid encapsulation solutions
Clinical Trials Antiemetics
DEA Appetite stimulants
Drug Enforcement Agency Entheogens
Drug Formulation Euphoriants
Elio Medicinal plants
Encapsulation Tetrahydrocannabinol
FDA Medical cannabis
Gelatin MMJ
Huntington API
Intellectual Property
Interstate Commerce
Marijuana
Multiple Sclerosis
Neurological Disorder
Orphan Drug
Pharmaceutical Company
Pharmacological
PhD
Prescription Drug
Protocol
Seizures
Ted Danson
THC
Treatment Modality
Vimeo

Semantics

Type Source Name
gene UNIPROT NR4A2
gene UNIPROT ALG3
gene UNIPROT SERPINA3
gene UNIPROT FHL5
disease MESH diagnosis
disease MESH seizures
disease MESH neurological disorder
disease MESH essential tremors
drug DRUGBANK Gelatin
gene UNIPROT TPI1
gene UNIPROT HAVCR1
gene UNIPROT TIMELESS
gene UNIPROT ARHGEF5
disease MESH chronic diseases
gene UNIPROT RXFP2
disease MESH suffering
gene UNIPROT PDC
drug DRUGBANK Alpha-1-proteinase inhibitor
gene UNIPROT FAM155B
disease DOID multiple sclerosis
disease MESH multiple sclerosis
drug DRUGBANK Cannabidiol
gene UNIPROT INPP5D
disease MESH Development
drug DRUGBANK Medical Cannabis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *